November 10, 2013

New At the Meeting program focuses on vaccination compliance in pigs

Audio program addresses monitoring and expectations of various vax protocols

Leading swine veterinarians address overall vaccination compliance issues critical to effectively managing Mycoplasma hyopneumoniae and porcine circovirus in the latest At the Meeting (ATM) program, produced by Dr. Bob Morrison, University of Minnesota.  

This program features Mike Eisenmenger, DVM, Swine Vet Center; Jeff DeWeese, DVM, Iowa Select Farms; and Brian Payne, DVM, technical manager at Boehringer Ingelheim Vetmedica, Inc., discussing the importance of vaccination compliance, monitoring and assessment protocols that ensure effective immunization against mycoplasma and circovirus in today’s production systems. In addition, the group of swine practitioners addressed the benefits and challenges of one-dose and two-dose vaccination programs, reasonable expectations for vaccine efficacy and strategies for improving overall compliance to improve respiratory disease control in grow-finish production operations.

To download or listen to the Vaccination Compliance At the Meeting program, go to Past At the Meeting programs are also available at The At the Meeting programs are sponsored by Boehringer Ingelheim Vetmedica, Inc.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information about Boehringer Ingelheim, please visit

Contact Information

  • Boehringer Ingelheim Vetmedica, Inc.

    3902 Gene Field Road
    St. Joseph, Missouri 64506